MX2017007946A - Metodos para tratar la calcificacion de tejidos. - Google Patents

Metodos para tratar la calcificacion de tejidos.

Info

Publication number
MX2017007946A
MX2017007946A MX2017007946A MX2017007946A MX2017007946A MX 2017007946 A MX2017007946 A MX 2017007946A MX 2017007946 A MX2017007946 A MX 2017007946A MX 2017007946 A MX2017007946 A MX 2017007946A MX 2017007946 A MX2017007946 A MX 2017007946A
Authority
MX
Mexico
Prior art keywords
calcification
npp1
treating tissue
provides
methods
Prior art date
Application number
MX2017007946A
Other languages
English (en)
Inventor
Quinn Anthony
Hsia Nelson
Lynette ASKEW Kim
KHAN Tayeba
Cheng Zhiliang
Charles O'neill W
grabowski Gregory
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2017007946A publication Critical patent/MX2017007946A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención proporciona un método para tratar la deficiencia de NPP1 o una enfermedad asociada con NPP1 tal como la calcificación arterial idiopática infantil (IIAC), pseudoxantoma elástico, calcificación vascular en enfermedad renal crónica (VCCKD), resistencia a la insulina, raquitismo hipofosfatémico, isquemia del miocardio, calcificación de articulaciones, estrías angioides, y osificación del ligamento longitudinal posterior de la espina. La presente invención proporciona un método para tratar la calcificación de tejidos al administrar NPP1 soluble para producir un incremento transitorio en los niveles de pirofosfato en suero.
MX2017007946A 2014-12-19 2015-12-18 Metodos para tratar la calcificacion de tejidos. MX2017007946A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094943P 2014-12-19 2014-12-19
US201562249781P 2015-11-02 2015-11-02
PCT/US2015/066646 WO2016100803A2 (en) 2014-12-19 2015-12-18 Methods of treating tissue calcification

Publications (1)

Publication Number Publication Date
MX2017007946A true MX2017007946A (es) 2017-09-15

Family

ID=56127864

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017007946A MX2017007946A (es) 2014-12-19 2015-12-18 Metodos para tratar la calcificacion de tejidos.
MX2022011281A MX2022011281A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.
MX2023006083A MX2023006083A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022011281A MX2022011281A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.
MX2023006083A MX2023006083A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Country Status (14)

Country Link
US (2) US10493135B2 (es)
EP (2) EP3967755B1 (es)
JP (3) JP2018500315A (es)
KR (1) KR20170095367A (es)
CN (1) CN107109381A (es)
AU (1) AU2015364411A1 (es)
BR (1) BR112017012928A2 (es)
CA (1) CA2971414A1 (es)
CO (1) CO2017006032A2 (es)
ES (1) ES2899895T3 (es)
HK (1) HK1245662A1 (es)
MX (3) MX2017007946A (es)
RU (1) RU2770698C2 (es)
WO (1) WO2016100803A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
EP3967755B1 (en) * 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
RU2021129201A (ru) 2015-05-19 2021-11-09 Йейл Юниверсити Композиции для лечения патологических состояний кальцификации и способы их применения
WO2017218786A1 (en) 2016-06-16 2017-12-21 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
AU2017306549A1 (en) 2016-08-05 2019-02-21 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
CA3096821A1 (en) * 2017-09-27 2019-04-04 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
CA3099266A1 (en) * 2018-05-08 2019-11-14 Yale University Compositions and methods for reducing progression of nephrolithiasis
WO2020047520A1 (en) * 2018-08-31 2020-03-05 Yale University Enpp1 polypeptides and methods of using same
AU2020207967A1 (en) * 2019-01-18 2021-07-29 Inozyme Pharma, Inc. Treatment of diseases involving deficiency of ENPP1 or ENPP3
BR112022024958A2 (pt) * 2020-06-09 2022-12-27 Inozyme Pharma Inc Proteínas enpp1 solúveis e usos das mesmas
AU2021383830A1 (en) * 2020-11-19 2023-06-22 Inozyme Pharma, Inc. Treatment of enpp1 deficiency and abcc6 deficiency

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
ATE319825T1 (de) 1997-11-07 2006-03-15 Trillium Therapeutics Inc Verfahren und zusammensetzungen zur immunomodulation
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
AU784285B2 (en) 1999-12-24 2006-03-02 Genentech Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
DE60140349D1 (de) 2000-02-23 2009-12-17 Pxe Internat Inc Methoden und zusammensetzungen zur diagnose und behandlung von pseudoxanthoma elasticum und ähnlichen zuständen
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
WO2004001064A2 (en) 2002-06-21 2003-12-31 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
SG193024A1 (en) * 2011-03-11 2013-10-30 Synageva Biopharma Corp Npp1 fusion proteins
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
EP3967755B1 (en) 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
RU2021129201A (ru) 2015-05-19 2021-11-09 Йейл Юниверсити Композиции для лечения патологических состояний кальцификации и способы их применения
CA3005142A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same

Also Published As

Publication number Publication date
JP2022003048A (ja) 2022-01-11
EP3234116A2 (en) 2017-10-25
EP3234116A4 (en) 2018-08-01
MX2022011281A (es) 2022-10-18
CO2017006032A2 (es) 2017-10-20
EP3967755A1 (en) 2022-03-16
MX2023006083A (es) 2023-06-19
JP2018500315A (ja) 2018-01-11
RU2770698C2 (ru) 2022-04-21
HK1245662A1 (zh) 2018-08-31
USRE49529E1 (en) 2023-05-16
US20180318400A1 (en) 2018-11-08
WO2016100803A3 (en) 2016-08-04
EP3234116B1 (en) 2021-09-08
CN107109381A (zh) 2017-08-29
AU2015364411A1 (en) 2017-06-08
KR20170095367A (ko) 2017-08-22
JP2024010052A (ja) 2024-01-23
EP3967755B1 (en) 2024-03-27
CA2971414A1 (en) 2016-06-23
RU2017119466A3 (es) 2019-12-20
ES2899895T3 (es) 2022-03-15
US10493135B2 (en) 2019-12-03
BR112017012928A2 (pt) 2018-05-15
WO2016100803A2 (en) 2016-06-23
RU2017119466A (ru) 2019-01-21

Similar Documents

Publication Publication Date Title
MX2022011281A (es) Npp1 para usarse en el tratamiento de calcificacion de tejidos.
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2021000848A (es) Compuestos y sus usos para modular la hemoglobina.
EA201791093A1 (ru) Антитела к cd47, способы и применение
PH12014502437A1 (en) Anti-egfr antibodies and uses threof
MY175708A (en) Dna antibody constructs and method of using same
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
MX2015011509A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
MX2021003740A (es) El control efectivo y eficaz del fosfato serico para una osificacion optima.
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2017000306A (es) Metodos para tratar hipotension.
EA201500670A1 (ru) Egfr-направленная терапия неврологических нарушений и боли
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2018002304A (es) Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2018011512A (es) Uso de insulina para promover el vaciamiento gástrico.
MX2017013669A (es) Composiciones para el tramiento del cancer.
EP4328245A3 (en) Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations